BioSpace News Archive

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Zevra Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000 ® Index and small-cap Russell 2000 ® Index in accordance with the 2023 Russell indexes annual reconstitution.

DiagnaMed Holdings Corp. is pleased to announce an update of CERVAI™, the Company’s proprietary AI brain health platform.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MAPLE-HCM a Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.

CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study.

Jasper Therapeutics, Inc., a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, announced the appointment of Scott Brun, M.D., to Jasper’s Board of Directors.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced that interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study indicate minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment.

Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Regulus Therapeutics Inc today announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease).